Objectives/Hypothesis: In many cancers, varying regions within the tumor are often phenotypically heterogeneous, including their metabolic phenotype. Further, tumor regions can be metabolically compartmentalized, with metabolites transferred between compartments. When present, this metabolic coupling can promote aggressive behavior. Tumor metabolism in papillary thyroid cancer (PTC) is poorly characterized.
INTRODUCTION
Many human cancers display significant tumor heterogeneity, and different regions or compartments within the tumor display varying metabolic phenotypes. Coupling between these metabolic compartments may allow for transfer of high energy metabolites from one compartment to another to meet the high bioenergetic demands of tumorigenesis. This intratumoral metabolic heterogeneity has been demonstrated in many cancer types, such as breast and head and neck squamous cell carcinoma, and is associated with poor outcomes. [1] [2] [3] [4] Cancer cells at the leading edge of growth exploit adjacent glycolytic cancer-associated fibroblasts (CAFs), utilizing their metabolic byproducts, such as lactate and pyruvate, to perform oxidative phosphorylation (OXPHOS). 5 Accordingly, a two-compartment model of tumor metabolism was proposed for which carcinoma cells generate oxidative stress in adjacent fibroblasts, leading to increased production of catabolites such as lactate, glutamine, and ketone bodies. 1, 5 These catabolites are taken up by carcinoma cells and serve as substrates for OXPHOS and promote tumorigenesis. [6] [7] [8] Specifically, metabolic coupling between glycolytic fibroblasts and cancer cells with high OXPHOS metabolism promotes tumor growth by increasing proliferation and inducing resistance to apoptosis in cancer cells. 9 There has been little research on the metabolism of papillary thyroid cancer (PTC), but studies suggest that metabolic dysregulation does occur in this disease. Papillary thyroid cancer thyrocytes have more abundant mitochondria than normal thyrocytes. 10 Furthermore, a genome-wide expression analysis in PTC identified pathways involved in mitochondrial OXPHOS and fatty Editor's Note: This Manuscript was accepted for publication October 29, 2015 .
Research reported in this article was supported by the National Cancer Institute of the National Institutes of Health (K08 CA175193-01A1 and P30CA056036) and the American Head and Neck Society/ American Academy of Otolaryngology Head and Neck Surgery Young Investigator Combined Grant (314313 acid synthesis as being associated with more aggressive disease. 11 Of the differentially enriched gene sets, three of the 11 that were associated with mortality were related to OXPHOS and mitochondrial metabolism. 11 Furthermore, tumorigenesis in PTC is thought to be caused in over 70% of cases by abnormalities in the mitogen-activated protein kinase (MAPK)-signaling pathway, which includes mutations in Ras, receptor tyrosine kinase (RET)/PTC, and BRAF. [12] [13] [14] Whereas links between MAPK signaling and altered cell metabolism have not been studied specifically in PTC, RAS-related alterations in MAPK signaling result in altered cellular metabolism. Cancer cells with active RAS have increased glucose uptake and catabolism, increased reactive oxygen species, and require OXPHOS for proliferation and tumorigenesis. 15 Conversely, RAS activation in fibroblasts drives glycolysis. 16 These glycolytic fibroblasts generated by oncogenic transformation with RAS activation promote tumor growth. 17 The current study sought to identify groups of PTC patients with and without advanced disease to assess for differences in their metabolic phenotypes. Translocase of the outer mitochondrial membrane 20 (TOMM20) was used as a marker of OXPHOS and monocarboxylate transporter 4 (MCT4) was used as a marker of glycolytic metabolism. Translocase of the outer mitochondrial membrane 20 is a central component of the receptor complex that is responsible for the recognition and translocation of cytosolically synthesized mitochondrial proteins and has been shown to be an indicator of functional mitochondrial mass and of OXPHOS. 2, 18, 19 Monocarboxylate transporters are a class of membrane-bound proteins involved in the influx and efflux of small metabolites such as lactate, pyruvate, and ketone bodies. 4 Monocarboxylate transporter 4 is the main transporter involved in lactate efflux and a marker of glycolytic metabolism and oxidative stress. Its expression has been shown to be associated with poor outcomes in other cancers. 20 To our knowledge, this is the first study to investigate if multiple metabolic compartments exist in PTC.
MATERIALS AND METHODS

Subjects
The study protocol was approved by our institutional review board. Records from our institution from 2011 to 2014 were reviewed by surgical codes to identify patients that presented with PTC. We identified advanced PTC in 19 consecutive patients. Advanced PTC was defined as presence of lateral neck lymphadenopathy. Additionally, a cohort of 27 consecutive PTC patients without advanced disease that had undergone thyroid lobectomy or thyroidectomy was identified. Eleven patient samples with benign thyroid pathology were also studied. Patients were excluded if they had evidence of poor differentiation or anaplastic features. Patient data collected included age, sex, stage, tumor morphology, pathologic features, surgical, and clinical records. Also, metastasis, age, completeness of resection, invasion, and size (MACIS); age, metastasis, extent of disease, size (AMES); and age, grade, extent of disease, and size (AGES); and the American Thyroid Association (ATA) recurrence risk level was assessed. 21 
Tissue Samples
For all cases, the surgical resection specimens were reviewed to confirm the diagnosis of PTC by two thyroid pathologists. Noncancerous thyroid (NCT) adjacent to the tumor was used as an internal control when present (n 5 34 of 38 PTC specimens). Benign tissue specimens were also used as controls from six patients with a final diagnosis of nodular goiter (NG) and from five with a diagnosis of follicular adenoma (FA). Samples were stained by immunohistochemistry for TOMM20, which was from Santa Cruz Biotechnology (F-10, Santa Cruz, CA), and MCT4 was a kind gift of Nancy J. Philp, PhD, and has been described in detail. 22 Briefly, tissues for analysis were fixed in neutral buffered formalin and then embedded in paraffin. Sections (4 lm) were dewaxed; rehydrated through graded ethanols; and antigen retrieval was performed in 10 mM citrate buffer, pH 6.0, for 10 minutes using a pressure cooker. The sections were cooled, blocked with 3% hydrogen peroxide and then for endogenous biotin using the DakoCytomation Biotin Blocking Sytem (Dako, Carpinteria, CA). Sections were next incubated with 10% goat serum for 30 minutes, followed by primary antibodies overnight at 48C (Santa Cruz Biotechnology). Primary antibody binding was detected with a biotinylated speciesspecific secondary antibody (Vector Labs, Burlingame, CA), followed by a streptavidin-horseradish peroxidase conjugate (Dako). Immunoreactivity was revealed with 3, 3 0 diaminobenzidine (Dako). Sections were counterstained with hematoxylin.
Immunohistochemical staining was assessed via an empirically derived staining score for TOMM20 and MCT4. Each case was reviewed independently by two pathologists. The pathologists were blinded to clinical outcome and prior pathology report. TOMM20 was considered high when at least 70% of cells demonstrated strong, diffuse cytoplasmic staining. The remaining cases were considered low. Cancer and fibroblast staining patterns were studied and quantified independently. The fibroblasts in close proximity to the carcinoma cells were defined in this study as CAFs. All tumors present on a slide and its dominant staining pattern were considered when determining the percent of immune-positive cancer and CAF cells in a sample. MCT4 fibroblast staining was scored as high if greater than 30% of stromal fibroblasts stained strongly for MCT4.
Statistical Analysis
Statistical analysis was carried out for Immunohistochemical staining patterns of TOMM20 and MCT4 between specimens using logistic regression and Fischer's exact methods. The exact logistic regression model was used to evaluate the relationship between MCT4 and various endpoints at significance level of alpha 5 5%, with the help of R package elrm.
23,24
RESULTS
Patient Characteristics
The clinical characteristics are outlined in Table I . In the advanced stage PTC group, defined as having clinical adenopathy in the lateral neck, the mean age at diagnosis was 46 years. Pathologic characteristics of these patients are listed in Table I . Fourteen patients had classic PTC, whereas two had tall cell and three had mixed classic and follicular variants (FVs). Extrathyroidal extension was evident in 13 subjects; and five had extensive tumor extension extending to the esophagus, carotid sheath, or prevertebral muscles. Four subjects had evidence of perineural invasion (PNI). Thirteen subjects had extracapsular lymph node spread. Three patients had evidence of distant metastatic disease on presentation. All subjects except one had complete primary surgical resection. One patient had thyroid bed recurrence and subsequently underwent additional surgical resection to negative margins. All subjects in this advanced disease group received radioactive iodine with doses ranging from 50 to 200 mCI.
In the PTC group without advanced disease, the age ranged from 23 to 70 (mean 48). Eleven patients had FV-PTC, whereas 15 had classic and one had mixed classic and FV. One patient demonstrated minimal lymphovascular invasion (LVI), and one had microscopic extrathyroidal extension (ETE). No patients had clinically or ultrasonographically identified pathologic lymph nodes. Four patients received radioactive iodine treatment. All patients were free of disease after treatment. In the NCT control group, ages ranged from 31 to 80 years (mean 54). Five patients demonstrated FAs and six had nodular goiter NGs. Examples of hematoxylin and eosin staining of normal thyroid tissue, nodular goiter, FA, and papillary thyroid cancer are shown in Figure 1 .
TOMM20 Protein Expression in Thyrocytes and Fibroblasts
Mitochondrial OXPHOS was assessed within the populations of noncancerous thyrocytes, PTC thyrocytes, and fibroblasts independently by TOMM20 immunohistochemistry. Two staining patterns for TOMM20 were found: 1) a strong diffuse staining pattern scored as high, or 2) a weak diffuse or a weak patchy staining pattern scored as low. In all nonneoplastic samples, including both adjacent nontumor thyrocytes from the PTC specimens and NG thyrocytes, TOMM20 expression was low ( Fig. 2A) . In contrast to this, all PTC thyrocytes from patients with and without advanced disease showed high expression of TOMM20 homogenously throughout the tumor (Fig. 2B ). In the nonadvanced group, four patients did not have strong staining, whereas all in the advanced group did; however, this difference was not statistically significant (P 5 0.36). In the FA specimens, all of the adenomatous thyrocytes showed high expression of TOMM20 compared to adjacent nontumor thyrocytes and nodular goiter samples. Low expression of TOMM20 was seen in all the fibroblast populations, which includes the cancerassociated fibroblasts and nontumor adjacent fibroblasts ( Fig. 2A, 2B ). High TOMM20 expression in PTC cells and FA is consistent with a highly functional mitochondrial mass, and this finding contrasts with low TOMM20 expression in thyrocytes in NG, NCT, CAFs, and normal fibroblasts or nontumor adjacent fibroblast populations.
MCT4 Protein Expression in Thyrocytes and Fibroblasts
Fibroblasts in NCT tissue demonstrated low MCT4 staining in 43 of 44 cases (Fig. 3A) . In the NG specimens, all samples demonstrated low MCT4 expression in fibroblasts. In the FA group, the fibroblasts around the adenoma and throughout the rest of the gland demonstrated low MCT4 staining in four of five cases. In a single FA case, MCT4 was elevated around the adenoma yet was negative throughout the rest of the gland. In the PTC group with advanced disease, all 19 cases demonstrated high MCT4 staining in the CAFs. In the PTC group without advanced disease, elevated MCT4 expression in CAFs was evident in the CAFs in 17 out of 27 specimens (Table  II) (Fig. 4) . Hence, the pattern of CAF MCT4 expression is statistically different in the advanced group compared to the group without advanced PTC (P < 0.01). When only classic variant of PTC was analyzed (FV-PTC excluded), only 10 of 17 showed high MCT4 staining, which was also statistically significantly different from the advanced PTC group (P < 0.01).
None of the specimens with low MCT4 in the CAFs demonstrated evidence of any negative prognostic or aggressive features such as ETE; LVI; PNI; clinical adenopathy; elevated AMES score; or intermediate score; or intermediate or high ATA risk of recurrence (Table II) . Moreover, low MCT4 staining in CAFs correlated with a low AMES score (P 5 0.002) and AGES score (P 5 0.004), and thus a better prognosis. Low MCT4 staining in CAFs also correlated with low ATA risk of recurrence (P 5 0.001) and with the absence of ETE (P 5 0.004). Stromal staining also correlated with comparison of T1 to T2 versus T3 to T4 tumors for the overall group (P 5 0.047). Cancer-associated fibroblasts MCT4 staining did not correlate with the presence of Hashimoto's thyroiditis (P 5 0.74) (Table III) .
DISCUSSION
This study suggests that different metabolic compartments exist within the PTC tumor and that metabolic changes in CAFs are associated with tumor behavior. Cancer-associated fibroblasts with high MCT4 staining, which are a marker of glycolysis, were found in all cases of advanced PTC. No tumors with low fibroblast MCT4 staining demonstrated advanced disease or aggressive features. Low fibroblast MCT4 staining was associated with lower MACIS, AMES, AGES, and ATA risk levels and the absence of ETE. TOMM20 is a membrane transporter in mitochondria that regulates mitochondrial metabolism; its expression correlates with mitochondrial OXPHOS. 2, 18, 19 Papillary thyroid cancer specimens demonstrated high TOMM20 staining, whereas noncancerous thyrocytes stained low, suggesting that there is increased OXPHOS in cancer cells. Our results are consistent with studies in other tumors, such as in breast cancer where higher mitochondrial metabolism is found in carcinoma cells compared to noncancerous ductal cells that are their normal counterparts. 25 It is likely that oncogene metabolic rewiring leads to increased mitochondrial metabolism in the carcinoma cells of PTC, with high TOMM20 staining. The mechanisms by which genetic abnormalities in PTC drive metabolic reprogramming will need to be determined.
In this study, cancer cells in PTC expressed TOMM20 highly and diffusely throughout the tumor. Interestingly, this staining pattern contrasts with staining in head and neck squamous carcinoma (HNSCC) in which TOMM20 is more highly expressed in the cancer cells in the periphery of the tumor. Head and neck squamous carcinoma tumors typically have very hypoxic regions. 26 Hypoxia would not only limit OXPHOS in the tumor cells, but may also create an additional glycolytic compartment in the tumor. It has been proposed that hypoxia drives multicompartment metabolism and metabolic coupling. 27 Head and neck squamous carcinoma appears to have the ability to couple this glycolytic compartment to the oxidative compartment at the leading edge of the tumor, which correlates with worse prognosis. The absence of this compartment in PTC specimens may suggest a lower ability to couple tumor compartments in PTC and may provide an explanation for the general lack of aggressive behavior in most PTC specimens compared to HNSCC. Future work will be required to assess hypoxia as a driver of tumor metabolism in PTC.
Furthermore, FA specimens also demonstrated increased TOMM20 staining, which may suggest that accumulation of metabolic abnormalities is a stepwise process in thyroid neoplasia. Further study would be required to investigate this process. High mitochondrial metabolism may not be sufficient to drive aggressive behavior in PTC given the fact that the OXPHOS marker TOMM20 is upregulated in both aggressive PTCs such as advanced stage disease, and in more indolent diseases such as low-stage PTC and even FAs. We suspect that metabolic rewiring may occur prior to metabolic coupling, and the degree to which metabolic coupling is achieved may determine the level of aggressive behavior in a given tumor. It may be that the cancer cells have little supply of glycolytic metabolites, either due to the lack of abundant transformed fibroblasts compartment that releases catabolites-as is seen in other tumors such as breast cancer-or due to a lack of cancer cell heterogeneity with a highly catabolic subtype of cancer cells that release catabolites-as seen in HNSCC. 28 Alternatively, the cancerous thyrocyte cells may lack the ability to effectively create or utilize these compartments for growth and invasion. Future studies should be conducted to test such hypotheses because PTC may offer a unique model to identify critical early steps in the transformation to aggressive cancer.
The current study adds to a body of literature supporting the role of mitochondrial metabolism in human cancers. 5, 29 It had been thought that human cancer cells used glycolysis universally to generate ATP based on cell culture experiments. 30 Interestingly, detailed metabolic characterization of cancer cells cultured homotypically with high glucose reveals high rates of glycolysis, whereas experiments that include lower glucose levels with alternative metabolic substrates such as lactate, pyruvate or fatty acids, or the presence of stromal cells show a shift toward mitochondrial metabolism or OXPHOS and more aggressive features. 5, 29, 31 It is now recognized that cancer cells frequently up-regulate many metabolic pathways compared to their noncancerous counterparts and do not rely exclusively on glycolysis to generate ATP. 32 Future studies will need to determine if certain metabolic features contribute to PTC aggressiveness. In accordance with Paget's seed-and-soil hypothesis that the interactions between cancer cells and their microenvironment are critical in cancer progression, 33 the role of metabolic interactions between carcinoma and stromal cells in PTC progression needs to be further explored. Cancerassociated fibroblasts in PTC demonstrated higher MCT4 expression compared to normal fibroblasts and compared to normal and cancerous thyrocytes. This suggests that fibroblasts adjacent to cancerous thyrocytes display a glycolytic metabolic phenotype distinct from normal fibroblasts. MCT4 is a marker of oxidative stress and glycolytic metabolism, and it induces efflux of lactate out of the cells. 20 Studies have shown in other cancers that stromal cells have high catabolism, which supplies cancer cells with high-energy metabolites. 8, 29 Cancer cells in turn use these metabolites for OXPHOS. This mechanism of metabolic coupling has been demonstrated in breast, ovarian, and prostate cancer and lymphomas. 5, 31, 34, 35 The current study adds to a body of literature describing metabolic compartmentalization in tumors of the head and neck region.
The relationship between tumor glycolysis, as measured by MCT4 staining and tumor uptake on positron emission tomography (PET) scans, has not previously been studied. Our study demonstrates that low MCT4 staining correlates with markers of low risk PTC, including less extrathryoidal extension and clinical lymphadenopathy. A study by Kim et al. has shown that low-PETavidity PTC specimens also have low-risk features, including lower lymphovascular invasion and smaller tumor size. 36 Data on PET avidity were not available for our patients, but future studies may be able to compare PET findings in PTC to MCT4 staining and other metabolic markers.
Targeting the metabolism of cancer cells or their adjacent fibroblasts may offer a novel therapeutic strategy in PTC. OXPHOS inhibitors may be effective anticancer drugs in PTC because there is homogenously high expression of the OXPHOS marker TOMM20. No potent OXPHOS inhibitors are approved by the U.S. Food and Drug Administration. However, there is some data to suggest that the weak OXPHOS inhibitor metformin has activity in PTC. Metformin was associated with a higher remission rate in a retrospective cohort of subjects with differentiated thyroid cancer, and where PTC was the most common histology. 37 Metformin induced the apoptosis of cancer cells and reduced tumor growth in a xenograft model of PTC 38 Metformin's beneficial effects in thyroid cancer, however, may be due to nonmitochondrial effects because it improves insulin resistance and reduces insulin levels, which drives thyroid proliferation or cancer.
39 Metformin may also reduce TSH level, which could suppress the growth of thyroid carcinoma cells, and therefore have protective properties against the development and progression of PTC. 39 Use of metformin in patients at risk for PTC may prove to be protective against the development or progression of this disease. 39 
CONCLUSION
In conclusion, metabolic markers suggest that, in advanced stage PTC, thyrocytes have high mitochondrial metabolism and adjacent fibroblasts have high glycolysis. Metabolic coupling and catabolite transfer may occur in PTC between these two tumor compartments (Fig. 5) . The intensity of TOMM20 and MCT4 staining in PTC cancer cells and fibroblasts, respectively, will need to be studied as a prognostic and predictive biomarker. A cancer cell mitochondrial compartment and a fibroblast glycolytic compartment in PTC may help us understand how PTC cells obtain energy to survive, proliferate, and metastasize. The answer may be that multiple tumor compartments with glycolysis in fibroblasts and OXPHOS in cancer cells allow more efficient tumor metabolism. Fig. 5 . Model of metabolic coupling. As the cancer cell influences the fibroblast to become more metabolically reliant on glycolysis, the fibroblasts export more high energy nutrients, such as lactate, pyruvate, and ketones, via monocarboxylate transporter 4. These in turn can be taken up by the cancer cells and utilized for mitochondrial respiration to produce greater quantities of adenosine triphosphate and fuel anabolic growth. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
